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Aidan Nowak
Public Health Law—C. Coleman Fall 2018
AWR Paper
The Cost of Living:
The Impact of the Increasing Cost of Pharmaceutical Drugs on Public Health
I.

Introduction
The rise in pharmaceutical prices has become a growing public health concern, particularly

in a society where approximately 50% of all Americans take at least one prescription drug.1 From
2008 through 2015, the price of brand name drugs increased by 164%.2 The twenty most
commonly prescribed brand name drugs offered under Medicare’s Part D program has increased
approximately 12% every year.3 The Center for Medicare and Medicaid Services (“CMS”)
predicts an average increase of 6.3% per year for prescription drugs.4
The rising pharmaceutical costs impacts many different constituents. Most directly,
individual purchasers bear the greatest burden and many must choose between the cost of medicine
and foregoing treatment.5 Insurance companies also face increased costs of insuring individuals.
Government budgets, at the federal and state levels, swell to sustain funding for Medicare and
Medicaid coverage. Conversely, pharmaceutical companies stress a need to generate suitable
profit margins and funds for additional research and development. Without proper remediation,
pharmaceutical costs may have a detrimental effect on the nation’s economy and public health.

1

CENTER FOR DISEASE CONTROL AND PREVENTION, PRESCRIPTION DRUG USE IN THE PAST 30 DAYS BY SEX, RACE,
AND H ISPANIC ORIGIN, AND AGE: UNITED STATES, SELECTED YEARS 1988-1994 THROUGH 2011-2014 (2017),
https://www.cdc.gov/nchs/data/hus/2017/079.pdf.
2
GLEN STETTIN AND ROCHELLE HENDERSON, EXPRESS SCRIPTS 2015 DRUG TREND REPORT 8 (2016).
3
UNITED STATES SENATE HOMELAND SECURITY & GOVERNMENTAL AFFAIRS COMMITTEE, MINORITY OFFICE,
115TH CONG., MANUFACTURED CRISIS: HOW DEVASTATING DRUG PRICE INCREASES ARE HARMING AMERICA’S
SENIORS 3 (2018).
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CENTER FOR MEDICARE AND MEDICAID SERVICES, NATIONAL HEALTH EXPENDITURE PROJECTIONS 2016-2025
(2017).
5
Timothy Kelley, When the Cost of Medications Keeps Patients from Taking Them, MANAGED CARE (June 3,
2018), https://www.managedcaremag.com/archives/2018/6/when-cost-medications-keeps-patients-taking-them.
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This paper will discuss (i) the causes of these increasing costs, (ii) the impacted parties, (iii)
measures taken and proposed by federal and state governments, (iv) the challenges with the taken
and proposed measures, and (v) lastly, propose four strategies to combat rising pharmaceutical
costs.
II.

Background

A. What are Pharmaceutical Drugs?
The purchase of prescription and over-the-counter drugs determines the success of the
pharmaceutical industry. Prescription drugs can be separated into two primary categories: (1)
brand-name drugs; and (2) generic drugs. Each play an integral role in the pharmaceutical industry
and contribute to price fluctuations within the market.
The Food and Drug Administration (FDA) defines brand-name drugs as “a drug marketed
under a proprietary, trademark-protected name.”6 Brand-name drugs are researched, developed
and tested by pharmaceutical companies, large and small. At some point during the development
phase, companies then file for patent protection.7 An approved patent protects the drug formula
from being copied or marketed, affording a company with years of protection against competition.
In addition to patent protection, the FDA can grant brand-name drugs “exclusivity;” thereby,
allowing for an additional period of time when a brand-name drug is protected from generic drug
competition. 8 As such, brand-name drugs typically charge a higher price.
A generic drug is “the same as a brand-name drug in dosage, safety, strength, how it is
taken, quality, performance and intended use.”9 The primary difference is that the generics do not

6

Food and Drug Administration, Glossary of Terms, FOOD AND DRUG ADMINISTRATION (Nov. 14, 2017),
https://www.fda.gov/drugs/informationondrugs/ucm079436.htm#B.
7
DEPRESSION AND BIPOLAR SUPPORT ALL., GENERIC AND BRAND NAME DRUGS: UNDERSTANDING THE BASICS 3
(2007).
8
FOOD AND DRUG ADMINISTRATION, EXCLUSIVITY AND GENERIC DRUGS: WHAT DOES IT MEAN? (2018).
9
Food and Drug Administration, supra note 6.
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have a patent and, oftentimes, do not operate under a brand name. As such, generic drugs can be
expected to have equal effect and no difference when substituted for the brand-name product.10
Moreover, Generic drugs are typically cheaper than their brand-name counterparts.
B. Pharmaceutical Pricing Trends
Pharmaceutical pricing has remained a growing public health concern since the early 1990s
as U.S. drug spending grew between 11 and 17% per year. As more complex and expensive drugs
were developed, insurance plans utilized formularies and co-payments to keep drug costs low.11
Additionally, drug manufacturers began offering rebates and discounts in order to decrease the
number of drugs excluded from coverage.12 As prices rose, private insurers took other means to
quell the increases in net drug prices by closing formularies to manage drug spending and
negotiating higher rebates and discounts from drug manufacturers.13 However, the narrative
remains the same approximately thirty years later; pharmaceutical prices continue to rise. As
previously stated, from 2008 through 2015, the price of brand-name drugs increased by 164%14;
with brand price inflation nearly doubling between 2011 and 2015.15 In the U.S., cancer drugs
routinely cost $10,000 per month.16 Twenty of the most commonly prescribed brand-name drugs
offered under Medicare’s Part D program increased approximately 12% annually from 2012
through 2017.17
As pharmaceutical prices increased, so did prescription drug spending. Between 2006 and

10

Id.
THE UNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICES, AMERICAN PATIENTS FIRST: THE TRUMP
ADMINISTRATION BLUEPRINT TO LOWER DRUG PRICES AND REDUCE OUT-OF-POCKET COSTS 13 (2018).
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Id.
13
Id.
14
GLEN STETTIN, ROCHELLE HENDERSON, supra note 2 at 8.
15
Id.
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Robert Langreth, Drug Prices, BLOOMBERG, May 11, 2018, https://www.bloomberg.com/quicktake/drug-prices.
17
UNITED STATES SENATE HOMELAND SECURITY & GOVERNMENTAL AFFAIRS COMMITTEE, MINORITY OFFICE,
115TH CONG., MANUFACTURED CRISIS: HOW DEVASTATING DRUG PRICE INCREASES ARE HARMING AMERICA’S
SENIORS 2 (2018).
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2015, retail prescription drug spending increased by an average of approximately 4.8% annually.18
For much of this time, the use of generic drugs limited price increases.19 However, drug spending
in 2014 and 2015 grew by an astounding 12.4% and 9% respectively.20 These figures are even
more overwhelming when compared to the average rate of inflation, between 2006 and 2016, of
1.8%.21
Americans spend more on drugs than the rest of the world. On average, Americans spend
$1,200 per year on pharmaceuticals.22 Switzerland, the second highest, spends $1,080.23 Canada
spends $860; Germany spends $777; France spends $663; and the United Kingdom spends $476.24
Increased spending is not a distinguishable difference. U.S. prices for the world’s top-twenty
medicines are, on average, three times higher than in Britain.25 For example, Roche Holding AG’s
Herceptin breast cancer drug, after rebates of roughly 15%, still cost approximately 85% more in
the U.S. than in other high-income countries.26 After an estimated discount of 60%, AstraZeneca
charges twice as much in the U.S. for Crestor compared to Germany. A 2013 study that found that
20% of adults in the U.S. failed to complete a prescribed course of medicine because of cost. 27
Comparatively, Germany, Canada, and Australia had a rate of 10%.28

18

UNITED STATES SENATE HOMELAND SECURITY & GOVERNMENTAL AFFAIRS COMMITTEE, MINORITY OFFICE,
Supra note 3, at 3.
19
Robert Langreth, Drug Prices, BLOOMBERG, May 11, 2018, https://www.bloomberg.com/quicktake/drug-prices.
20
UNITED STATES SENATE HOMELAND SECURITY & GOVERNMENTAL AFFAIRS COMMITTEE, MINORITY OFFICE,
Supra note 3, at 3.
21
Kimberly Amadeo, U.S. Inflation Rate from 1929 to 2020, THE BALANCE (July 6, 2018),
https://www.thebalance.com/u-s-inflation-rate-history-by-year-and-forecast-3306093
22
Organisation of Economic Co-Operation and Development, Pharmaceutical Spending, OECD (Nov. 8, 2018),
https://data.oecd.org/healthres/pharmaceutical-spending.htm.
23
Id.
24
Id.
25
Ben Hirschler, Transatlantic Divide: How U.S. pays three times more for drugs, REUTERS (Oct. 12, 2015),
https://www.reuters.com/article/us-pharmaceuticals-usa-comparison/exclusive-transatlantic-divide-how-u-s-paysthree-times-more-for-drugs-idUSKCN0S61KU20151012.
26
Robert Langreth, Blacki Migliozzi, Ketaki Gokhale, The U.S. Pays a Lot More for Top Drugs Than Other
Countries, BLOOMBERG (Dec. 18, 2015), https://www.bloomberg.com/graphics/2015-drug-prices/.
27
Robert Langreth, Drug Prices, BLOOMBERG (May 11, 2018), https://www.bloomberg.com/quicktake/drug-prices.
28
Id.
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Under the current law and policy initiatives, the Centers for Medicare and Medicaid
Services (“CMS”) projects national health spending to grow at an average rate of 5.5% per year
from 2017 through 202629; totaling $5.7 trillion by 2026.30 Within health spending, CMS
anticipates that prescription drug costs will see the fastest annual growth among health care
expenditures over the next decade.31 Its February 2018 report, CMS projected a 2.3% acceleration
in prescription drug prices: from 2.1% in 2017 to 4.4% in 2018.32 This acceleration “reflects the
expectation that brand-name drug prices will more strongly influence growth in that year because
the dollar value of drugs losing patents in 2018 is smaller than in prior years.”33 Though drug
price growth is lower than previous years, CMS predicts that through 2025 pharmaceutical prices
will rise an average of 6.3% per year due to a greater use of specialty drugs such as those used for
genetic disorders and cancer.34
III.

Causes of the Increasing Costs
The cost of pharmaceutical drugs can be attributable to various factors including regulatory

advantages (patent and exclusivity durations), commercially creative approaches deployed by
manufacturers (discounts and rebates, “gag” clauses) and limitations on government’s ability to
intervene (absence of direct price regulation, and inability for Medicare to negotiate directly with
manufacturers).
Patent and “Exclusivity” periods give a manufacturer a non-competitive marketplace to
sell theirs drugs. A U.S. patent precludes another party, including generic drug makers, give a

29

CENTER FOR MEDICARE AND MEDICAID SERVICES, NATIONAL HEALTH EXPENDITURE PROJECTIONS 2016-2025
(2017).
30
Id.
31
CENTER FOR MEDICARE AND MEDICAID SERVICES, NATIONAL HEALTH EXPENDITURE PROJECTIONS 2017-2026
(2018).
32
Id.
33
Id.
34
CENTER FOR MEDICARE AND MEDICAID SERVICES, NATIONAL HEALTH EXPENDITURE PROJECTIONS 2016-2025
(2017).
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patent holder the exclusive right to exclude others from making, using, importing, and selling the
patented innovation for a limited period of time, typically twenty years.35 Manufacturers argue
that the protections and the related costs are necessary to recover years of research and
development costs. In certain cases, the FDA may grant a drug “exclusivity” for a period of time
to protect it from generic drug competition36 and promote a balance between innovation and
generic drug competition.37 Drugs may be granted exclusivity for a variety of reasons. Drugs that
feature a new chemical entity are given five-year exclusivity.38 Orphan drugs, defined as drugs
for a disease or condition affecting fewer than 200,000 people, are granted seven-year
exclusivity.39 A brand-name drug may receive three-year exclusivity if the drug’s active ingredient
can be delivered in a new way or be used to treat a different disease or condition.40 Exclusivity
and patent protections provide brand-name drugs a monopoly allowing them to charge higher rates.
Upon the expiration of patent and exclusivity protection, the cost of the brand-name drug
decreases; though typically not to the level of its generic counterparts due to recognition.
While “generics” cannot be granted patent protection, “the first generic drug applicant to
submit a substantially complete generic application” that challenges a brand-name drug’s patents
and satisfies regulatory and legal requirements may be eligible for a 180-day exclusivity period.41
The 180-day period begins from the first occurrence of either the date the sponsor begins
commercial marketing of the generic drug product or the date of a court decision holding “the
patent is invalid, unenforceable, or not infringed.”42 Prior to reaching the market, the generic drug

35

35 U.S.C. §1 et. Seq. (1999).
FOOD AND DRUG ADMINISTRATION, EXCLUSIVITY AND GENERIC DRUGS: WHAT DOES IT MEAN? (2018).
37
Id.
38
Id.
39
Id.
40
Id.
41
FOOD AND DRUG ADMINISTRATION, EXCLUSIVITY AND GENERIC DRUGS: WHAT DOES IT MEAN? (2018).
42
FOOD AND DRUG ADMINISTRATION, PATENTS AND EXCLUSIVITY 3 (FDA/CDER SBIA Chronicles, 2015).
36
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must be approved by the FDA. As such, the generic drug undergoes rigorous testing to ensure its
“substitutability” to its brand name counterpart.43 Testing must reveal that the generic drug
contains identical amounts of the same ingredient(s) as the brand-name product.44 Since the
chemical makeup is identical, generic drugs can be expected to have equal effect and no difference
when substituted for the brand-name product.45 Generic drugs are typically cheaper than their
brand-name counterparts costing on average between 80 to 85% less than brand name drugs.46 In
2010, the use of generic drugs saved consumers $158 billion.47
Discounts and rebates are used by pharmaceutical manufacturers as a means to provide the
purchaser a price reduction without impacting the manufacturer’s profit margin. In both scenarios
the manufacturer increases the list-price of the drug, with the understanding that price reductions
will be provided to entice purchasers and pharmacists. A discount is a reduction in the amount
that a seller charges a buyer48, typically a pharmacy, with the intent that the pharmacy will promote
that manufacturer’s product rather than a competitor’s.49 Discounts are provided in order to
increase the use of higher priced drugs.
Rebates also operate as a reduction in price with the intent of increasing sales. Unlike
discounts which are paid upon purchase, a buyer receives the benefit in the future. Such is
necessary because rebates are based upon product sales.50 While rebates for generic drugs are
paid to a pharmacy or wholesaler, rebates for patented, brand-name products are paid to the
pharmacy benefit managers (PBMs). PBMs operate as a healthcare intermediary and include

43

Food and Drug Administration, supra note 6.
Id.
45
Id.
46
FOOD AND DRUG ADMINISTRATION, FACTS ABOUT GENERIC DRUGS 2 (2009).
47
Id.
48
Norman V. Carroll, Discounts, Rebates, and Kickbacks, PHARMACY BUSINESS AND ECONOMICS BLOG (June 17,
2015), https://wp.vcu.edu/nvcarroll/2015/06/17/discounts-rebates-and-kickbacks/.
49
Id.
50
Id.
44
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companies such as CVS Health, Express Scripts, US Scripts, and Humana. PBMs represent health
insurers, union health plans, and government purchasers in the selection, purchase and distribution
of pharmaceuticals.51 Since PBMs influence which drug products are the most frequently used,
rebates are paid so a PBM will grant the drug exclusive or preferred status. Exclusive status
guarantees that the drug is the only one available on the formulary.52 Preferred status provides
that that drug’s copay is less than the copay for similar products.53 Rebates remain extremely
costly for pharmaceutical manufacturers.

In 2017, rebates paid by the thirteen largest

manufacturers totaled $150 billion, double those paid in 2011.54 Because health plans, PBMs and
wholesalers receive higher rebates and fees when list prices increase, there is little incentive to
control list prices.55
“Gag clauses” are commercial contracts between a pharmacy and a PBM that remain
largely invisible to consumers purchasers.56 These arrangements restrict pharmacists from
informing consumers about “available alternative pricing, including paying out-of-pocket,
generics or brand-name products that may be less costly, or those which may be comparatively
more suitable for a patient” than the prescribed drug.57
Government’s inability to impact drug pricing also significantly contributes to the problem.
Unlike Europe, the U.S. does not directly regulate pharmaceutical prices. As such, pharmaceutical
companies are able to set prices according to what they or the market dictates leading to U.S.

51

Cole Werble, Pharmacy Benefit Managers, HEALTHAFFAIRS (Sept. 14, 2017),
https://www.healthaffairs.org/do/10.1377/hpb20171409.000178/full/.
52
Carroll, supra note 48.
53
Id.
54
David Belk, Paul Belk, The Pharmaceutical Industry, True Cost of Healthcare Blog (2018),
http://truecostofhealthcare.org/the_pharmaceutical_industry/.
55
THE UNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICES, AMERICAN PATIENTS FIRST: THE TRUMP
ADMINISTRATION BLUEPRINT TO LOWER DRUG PRICES AND REDUCE OUT-OF-POCKET COSTS 17 (2018).
56
Id.
57
Richard Cauchi, Recent Approaches and Innovations in State Prescription Drug Laws, NATIONAL CONFERENCE
OF STATE LEGISLATURES (Oct. 1, 2018), http://www.ncsl.org/research/health/rx-costs.aspx#Rx_transparency.

Nowak

9

pharmaceutical prices being are among the highest in the world. From 2011 through 2017, the
thirteen largest pharmaceutical companies received 45% of its global revenue from the U.S.58 The
remaining 55% came from all other countries combined.59
Comparatively, European governments directly regulate prices using different
formulations. The most widely accepted formulation is “External Price Referencing” (“EPR”),
where is used in twenty-nine countries in the European Union as well as Iceland, Norway,
Switzerland, and Turkey.60 EPR is defined by the European Commission, the governing body of
the European Union, “as the practice of using the price(s) of a medicine in one or several countries
in order to derive a benchmark or reference price for the purposes of setting or negotiating the
price of a medicine in a given country.”61 The United Kingdom ‘s National Health Service
employs a “sufficient value for money” formula and has refused to pay for certain cancer drugs,
widely used in the U.S.62 As a result, pharmaceutical manufacturers are constricted when setting
prices in European markets; leading manufacturers to charge higher fees in the U.S. market.
More limiting is Medicare’s inability to negotiate drug prices with pharmaceutical
companies. Under the Social Security Act, Medicare “may not interfere with the negotiations
between drug manufacturers, pharmacies and PDP sponsors, and may not require a particular
formulary or institute a price structure for the reimbursement of covered Part D drugs.”63 By not
giving Medicare, one of the largest global purchasers of pharmaceuticals, the right to negotiate
prices, the average per capita costs within the Part D prescription drug program have risen and are

58

David Belk and Paul Belk, supra note 54.
Id.
60
Zachary Brennan, European Drug Prices: New Commission Report on What Policies Work and What Could
Work, REGULATORY AFFAIRS PROFESSIONALS SOCIETY (Feb. 25, 2016), https://www.raps.org/regulatoryfocus%E2%84%A2/news-articles/2016/2/european-drug-prices-new-commission-report-on-what-policies-workand-what-could-work.
61
Id.
62
Robert Langreth, Drug Prices, BLOOMBERG, May 11, 2018, https://www.bloomberg.com/quicktake/drug-prices.
63
42 U.S.C. 1395w-111(i)(1) (2017).
59
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projected to rise 4.7% annually over the next decade. 64
The length of patent and exclusivity protections, the various commercial approaches taken
by the drug companies and the government’s own imposed restraints to limit drug prices have,
collectively and individually, added to the size and scope of this national crisis. A crisis that
impacts individuals, companies and government budgets.
IV.

Parties to the Price Increases
Drug prices impact a variety of parties. Individuals, employers, and the government are

harmed from the increasing prices in their own ways. Meanwhile, pharmaceutical and insurance
companies derive an economic benefit from the increasing costs.
Individuals are the greatest impacted from increased pharmaceutical costs. A 2009 study
conducted by Elizabeth Warren found that 62.1% of all bankruptcies were due to medical bills.65
Moreover, the high cost of prescriptions are causing more and more patients to not fill or not
complete their course of treatment according to the Center for Disease Control and Prevention
(“CDC”).66 Skipping medications is known to worsen an individual’s health and quality of life,
resulting in higher medical costs. A study from the Annals of Internal Medicine found that a lack
of adherence to self-administered medications causes approximately 125,000 deaths in the United

64

Juliette Cubanski, Tricia Neuman, Searching for Savings in Medicare Drug Price Negotiations, KAISER FAMILY
FOUNDATION (Apr. 26, 2018), https://www.kff.org/medicare/issue-brief/searching-for-savings-in-medicare-drugprice-negotiations/ (From 2007 through 2013, the average per capita costs increased 2.4%, and increased 4.4%
between 2013 and 2016).
65
Kimberly Amadeo, Medical Bankruptcy and the Economy, THE BALANCE (May 16, 2018),
https://www.thebalance.com/medical-bankruptcy-statistics-4154729.
66
CENTERS FOR DISEASE CONTROL AND PREVENTION, STRATEGIES USED BY ADULTS TO REDUCE THEIR
PRESCRIPTION DRUG COSTS (2015) (The study states that 8% of adults in general do not take their medication to save
money. Additionally, the study notes that adults between 18 and 65 were twice as likely as those over 65 to not
take their medication. Moreover, 14% of uninsured adults, 10% of Medicaid patients and 6% of privately insured
patients do not take their medication to save money.)
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States67 and costs the U.S. health care system between $100 billion and $289 billion annually.68
Increased pharmaceutical costs also directly impacts employers. Under the Affordable
Care Act (“ACA”), employers are required to provide health insurance to full-time employees.
The increase in spending for pharmaceuticals has been a primary reason for annual increases of
employer health care costs.69 Retail drugs consist of approximately 21% of employer insurance
benefits.70 A 2017 survey by Mercer, a consultancy firm, found that 46% of employers would take
steps to cut costs through new strategies such as high-deductible health plans, which shift the
burden of initial medical costs to patients, but have lower monthly premiums.71
Pharmaceutical costs negatively impact the government as well. In 2017, the National
Health Expenditure, the official measurement of total healthcare spending, accounted for 17.9%
of the U.S.’s GDP.72

Medicare spending was 15% of the total federal budget in 2017 and is

projected to rise to 18 percent by 2028.73 Medicare benefit payments totaled $705.9 billion.74
Medicaid, ACA, and Children’s Health Insurance Program spending was 11% of the federal
budget in 2017.

Combined, Medicare and Medicaid spend $174 billion on prescription

medications in 2016.75

67

Viswanathan M, Golin CE, Jones CD, Ashok M, Blalock SJ, Wines RC, et al., Interventions to Improve
Adherence to Self-administered Medications for Chronic Diseases in the United States: A Systematic Review, 157
Annals of Internal Med.785–95 (2012).
68
Id.
69
Robert Galvin, Troyen Brennan, Can Employers Take a Bigger Role in Controlling Drug Costs, HEALTHAFFAIRS,
(Feb. 17, 2017), https://www.healthaffairs.org/do/10.1377/hblog20170217.058822/full/.
70
Rabah Kamal, Cynthia Cox, What are the recent and forecasted trends in prescription drug spending?,
PETERSON-KAISER HEALTH SYSTEM TRACKER (December 20, 2017), https://www.healthsystemtracker.org/chartcollection/recent-forecasted-trends-prescription-drug-spending/?_sf_s=recent+trends#item-start.
71
Divya Grover, Costly drugs to weigh on U.S. employers’ expenses in 2018: survey, REUTERS (Sept. 18, 2017),
https://www.reuters.com/article/us-usa-healthcare-survey/costly-drugs-to-weigh-on-u-s-employers-expenses-in2018-survey-idUSKCN1BT1FR.
72
CENTER FOR MEDICARE AND MEDICAID SERVICES, NATIONAL HEALTH EXPENDITURES 2017 HIGHLIGHTS 1 (2018).
73
Juliette Cubanski, Tricia Neuman, The Facts on Medicare Spending and Financing, KAISER FAMILY FOUNDATION
(June 22, 2018), https://www.kff.org/medicare/issue-brief/the-facts-on-medicare-spending-and-financing/.
74
CENTER FOR MEDICARE AND MEDICAID SERVICES, NATIONAL HEALTH EXPENDITURES 2017 HIGHLIGHTS 2 (2018).
75
Tami Luhby, Check out how much Medicare spends on drugs, CNN BUSINESS (May 15, 2018),
https://money.cnn.com/2018/05/15/news/economy/medicare-drug-spending/index.html.
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Insurance companies are also directly impacted and must manage drug prices. Increased
drug prices lead to increased costs of insurance.

However, rather than bearing the costs

themselves, insurance companies transfer the costs onto purchasers in the form of increased plan
prices or higher co-pays.76
With the demand for more cost control, pharmaceutical companies argue that drug prices
are high in order to bankroll development of future medical advances, that pharmaceutical
advances justify price, and restricting prices would harm innovation. Studies show the average
cost of developing a prescription drug which gains market approval is $2.6 billion.77 Much of their
defense is undermined by their own success. Estimated pharmaceutical and biotechnology sales
revenue increased from $534 billion to $775 billion from 2006 through 2015 with approximately
67% of all drug companies increasing profit margins during the same time.78 Interestingly, the
twenty-five largest pharmaceutical companies, had an average profit margin between 15 and 20%
compared an average profit margin for nondrug companies for the larges 500 globally of 4 to 9%.79
Additional facts further weaken that drug companies’ arguments. First, more than 50% of
important discoveries and 85% of basic discoveries are made in independent academic centers.80
Second, a study from the Journal of Clinical Oncology found that drug effectiveness does not
necessarily translate to cost effectiveness for cancer drug pricing. 81 Third, the median deal of

76

ELSEVIER CLINICAL SOL., THE IMPACT OF RISING GENERIC DRUG PRICES ON THE U.S. DRUG SUPPLY CHAIN 1
(2015).
77
Rick Mullin, Tufts Study Finds Big Rise in Cost of Drug Development, C&EN (Nov. 20, 2014),
https://cen.acs.org/articles/92/web/2014/11/Tufts-Study-Finds-Big-Rise.html.
78
UNITED STATES GOVERNMENT ACCOUNTABILITY OFFICE, DRUG INDUSTRY: PROFITS, RESEARCH AND
DEVELOPMENT SPENDING, AND MERGER AND ACQUISITION DEALS 1 (2017).
79
Id.
80
Hagop Kantarjian and Vivian Ho, Opinion, The Harm of High Drug Prices, U.S. NEWS (Dec. 12, 2016),
https://www.usnews.com/opinion/policy-dose/articles/2016-12-12/the-harm-of-high-drug-prices-to-americans-acontinuing-saga.
81
Bruce E. Hillner, Thomas J. Smith, Efficacy Does Not Necessarily Translate to Cost Effectiveness: A Case Study
in the Challenges Associated With 21st-Century Cancer Drug Pricing, 27 J. of Clinical Oncology 2111-13 (2009).
http://ascopubs.org/doi/pdf/10.1200/JCO.2008.21.0534
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mergers and acquisitions increased while the volume remained steady, suggesting that
manufacturers are buying drug discoveries and not developing them in-house.82 Fourth, research
and development equaled 17% of their revenue for the thirteen largest drug companies from 2011
through 2017.83 While the pharmaceutical companies’ arguments must be taken into account, they
must also be scrutinized carefully.
Any remedial action must take into consideration all parties so that advances in medications
can continue while allowing individuals to benefit from those innovations without damaging the
economic health of individual, employers and governments.
V.

Steps being taken—State Governments
Since 2015, states have enacted a wide variety of policy initiatives related to prescription

drug regulation, with more than 200 signed bills from forty-five states to affect pricing, payment,
and costs of prescription drugs.84 In 2018 alone, forty-one states enacted 121 bills regulating the
pharmaceutical industry.85 Legislation has been adopted by both Republican and Democrat
leaning states to signal bipartisan concern over this growing public health concern. State measures
include: (1) Drug cost transparency; (2) allowing for importation of prescription drugs from
Canada; (3) drug anti-price gouging; (4) drug co-payment limitations; and (5) determining
Medicaid prescription coverage based upon negotiation and cost effectiveness.86 Some measures
have been rejected by the courts as being unconstitutional.
First, more than 60 drug cost transparency bills have been proposed in thirty states across

82

Id.
David Belk, Paul Belk, supra note 54.
84
Richard Cauchi, Supra note 57.
85
National Conference of State Legislature, Statewide Prescription Drug Database: 2015-Present, NATIONAL
CONFERENCE OF STATE LEGISLATURES (November 11, 2018), http://www.ncsl.org/research/health/prescriptiondrug-statenet-database.aspx.
86
Richard Cauchi, Supra note 57.
83
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the country.87 Among these 60 bills, twenty-seven have been implemented in seventeen states,
and many more are still pending.88

Most notably, California and Vermont are considered

“pioneers” of drug transparency having been the first states to implement such plans. These bills,
which apply to both brand-name and generic drugs, are designed to identify the costs that
contribute to drug manufacturer expenses, list prices, and unveil the business practices of PBMs.89
PBMs are heavily scrutinized due to the secrecy of their business practices.
Generally, transparency bills require drug manufacturers to report the reasons behind drug
price increases that exceed 10% or more over a twelve-month period.90 The price increase
rationale must be in an understandable and appropriate format and are publicized.

The

transparency “give[s] hospitals access to pricing information that they could use when
communicating with manufacturers to establish rates.”91 Some believe drug price transparency
would hold manufacturers accountable for the cost of medications.92 Depending upon the specific
state’s requirements, failure to comply with the reporting requirements may result in fines up to
$10,000 per day.93 States with drug cost transparency laws often stipulate differing reporting
requirements. California, for example, places requirements on both pharmaceutical manufacturers
and health insurers.94 Manufacturers must provide purchasers with 60-day advance notification
of price increases “that exceeds a specified threshold” for prescription drugs currently on the
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market, including reasons and justifications for such increases.95 Manufacturers must also provide
justification of launch prices for new drugs.96 Health insurers filing rate information must report
specific cost information regarding prescription drugs covered under their plan, including generic,
brand-name, and specialty drugs and the percentage of their insurance premium that are
attributable to prescription drugs.97 Nevada, in addition to price increase reporting justifications,
requires the (i) reporting of free goods or compensation by sales representatives to licensed health
providers and (ii) the dollar value of manufacturer drug rebates they collect.98
Second, states have taken steps to increase competition through the importation of drugs.
In May 2018, Vermont enacted legislation that enabled the wholesale importation of prescription
drugs into Vermont from Canada.99 Since then, Colorado, Louisiana, Montana, New York,
Oklahoma, West Virginia, and Wyoming have introduced similar bills.100 These bills apply a
market-based approach to decreasing pharmaceutical prices by “providing more affordable
medicines from Canada, where prescription drugs cost on average 30 percent less than in the
United States.”101

The approach would create a state-administered system of wholesale

importation and distribution, limited solely to pharmaceuticals from Canada and by contracting
with a fully licensed, regulated Canadian supplier that is compliant with Canadian law. 102 The
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Canadian supplier would manage distribution to state-licensed pharmacies. Participating states
would decide the extent of coverage for public and private health plans and programs.
However, the state importation legislation requires federal approval, thereby delaying the
legislation’s implementation. Section 804 of the Medicare Prescription Drug, Improvement, and
Modernization Act of 2003 (“Section 804”) provides that the Health and Human Services
Secretary (“HHS Secretary”) may allow the importation of prescription drugs from Canada if it
can be proven that it will (1) pose no additional risk to the public’s health and safety and (2) result
in a significant reduction in the cost of covered products to the American consumer.103 Proponents
argue that importation would be safe and produce savings for American consumers. Specifically,
Section 804 would be satisfied because: (i) a state must select a Canadian supplier that is licensed
and regulated under Canadian law and could be licensed under state pharmacy or wholesaler law
as well; (ii) a state would select drugs that are approved for the Canadian market; (iii) participants
would agree to purchase and reimburse drugs at the import price and patient cost sharing would
be based upon the import price as well; (iv) states must monitor and audit the system for
compliance, safety, and savings; and (v) the legislation (a) allows for greater transparency for
consumers and (b) requires the imported products be distributed in-state only.
HHS does not seem t convinced of the legislation’s merits.104 However, there has yet to
be a HHS Secretary that has deemed Section 804’s standard to be satisfied. Alex Azar, the current
HHS Secretary, stated in May 2018 that programs designed to reduce pharmaceutical prices
through importation are “just a gimmick.”105 In dissent of importation programs, Azar referenced
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a 2004 analysis by the Congressional Budget Office (“CBO”) that determined that importation
would not have a meaningful impact on U.S. prescription drug prices. 106 Azar, relying upon
findings from four prior FDA commissioners, also stated that allowing drugs to come into the U.S.
from Canada raises safety concerns.107 Regardless of the potential benefits, importation from
Canada will not occur until approval by the HHS Secretary.
Another unique approach to tackle the rise in drug prices is the implementation of antiprice gouging laws. In October of 2017, Maryland became the first state to implement such a law,
which prohibited a manufacturer or wholesale distributor from engaging in “price gouging” in the
sale of an essential off-patent or generic drug.108

The act defined price gouging as “an

unconscionable increase in the price of a prescription drug.”109 An “unconscionable increase” was
further defined as an increase that “is excessive and not justified by the cost of producing the drug
or the cost of appropriate expansion of access to promote public health.”110 A manufacturer or
wholesale distributor determined to be in violation of the act faced numerous legal consequences,
including a civil penalty of $10,000 per violation or an action enjoining the sale of the medication
at the increased price.111 Ultimately, the act was challenged and struck down by the Fourth Circuit
Court of Appeals in April of 2018.112 The Court held that the act violated the Dormant Commerce
Clause because it directly regulated the price of transactions that occurred outside the state of
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Maryland.113 As such, the act imposed a significant burden on interstate commerce involving
prescription drugs.114 Since being struck down, similar bills in 16 other states have stalled, with
bills in 11 states no longer active.115
Fourth, legislation addressing cost-sharing and deductibles has been adopted in 20 states
across the country.116 This legislation implements caps on pharmaceutical pricing without directly
regulating the prices themselves, focusing primarily on specialty drugs that are typically more
expensive for consumers. In California, “cap the copay” legislation was enacted.117 This law
prohibits an individual health insurance policy or group health care service plan that provides
coverage for anticancer medications from requiring an enrollee to pay more than $250 in
copayments and coinsurance for a 30-day supply of an individual prescription.118 Alongside
California, 19 other states have adopted similar cost-sharing legislation.119 In January of 2018, the
Biotechnology Innovation Organization commissioned a report seeking to understand the
economic impact of prescription drug cost-sharing cap legislation.

The report found that,

compared to states without cost-sharing cap legislation, California could expect approximately a
one percent decrease in spending for individual plans and a three percent decrease for group
plans.120 However, the net paid costs would remain unchanged as insurers compensated for the
copayment and coinsurance cap by increasing premiums accordingly. Thus, any benefit may be
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substantially limited.
Fifth, a majority of states have implemented legislation, subject to CMS approval, that
determines Medicaid prescription drug coverage based upon negotiation and cost-effectiveness.121
Under this legislation, states have adopted four payment models for determining costeffectiveness: (1) establishing a Medicaid drug cap; (2) utilizing value-based contracting; (3) a
subscription-based payment model; and (4) a closed formulary approach. In 2017, New York
established a Medicaid drug cap to balance the growth of drug expenditures with the growth of
total Medicaid expenditures.122 Under New York’s law, New York’s Drug Utilization Review
Board follows a recommended target for the value of a Medicaid rebate to be paid by the
manufacturer to the State.123 If a satisfactory rebate agreement is not agreed upon, any noncooperating manufacturers are required to file a detailed financial report including, but not limited
to, the actual cost of developing, manufacturing, producing and distributing the drug; research and
development costs; administrative and marketing costs; the price of the drug when sold outside the
United States; the average rebates and discounts provided per payer type in the state; and the
average profit margin of each drug.124
In 2018, CMS approved Oklahoma legislation that utilized a value-based model. The
value-based model authorizes the state to negotiate supplemental rebate agreements for
pharmaceuticals involving value-based purchasing agreements with manufacturers that could
produce additional rebates for states if specific outcomes were not achieved.125 Thus, if certain
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clinical or cost benchmarks were not achieved, the drug manufacturer is required to provide
additional rebates to the state.126 Louisiana adopted a subscription-based payment model for
Hepatitis C drugs.127 Under this model, the state pays drug manufacturers for unlimited access to
the treatment for individuals enrolled in Louisiana’s Medicaid or correctional system.128 The cost
would be equal to or less than the state’s current expenditures for providing the medication to these
groups.129 Lastly, Massachusetts adopted a closed formulary approach. Under this approach, the
state would be not be required to cover every drug made by a manufacturer that participates in the
federal Medicaid rebate program.130 Instead, the law would have allowed the state to choose which
prescription drugs to cover according to cost effectiveness and their beneficiaries’ needs. 131
However, CMS denied the Massachusetts law because the proposal would have also preserved
statutory rebates.132

CMS stated that they would consider a closed-formulary approach in

Medicaid if the state agreed to forgo the available mandatory rebates through the Medicaid rebate
program.133
State legislative efforts have had mixed success. Some of the legislation has been effective
in curtailing increases in pharmaceutical costs, while the benefits of other legislation have been
blocked by the courts or a reluctant federal government.
VI.

Steps being taken—Federal Government
Alongside state legislation, the federal government has taken unilateral steps to curtail the
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rising costs of pharmaceuticals. In May of 2018, President Donald Trump’s administration
released the American Patients First blueprint to explain initiatives designed to lower drug prices
and reduce out-of-pocket costs for consumers.134 The blueprint’s initiatives are premised upon
increasing competition, improving negotiation, creating incentives to lower list prices, and
reducing patient out-of-pocket spending costs.135
Pursuant to its Drug Competition Action Plan, the FDA implemented two new policies in
2017 to increase competition in the pharmaceutical industry. First, the agency published a list of
off-patent, off-exclusivity, branded drugs without approved generics in order to improve
transparency and encourage the development and submission of new generic drug applications for
drugs with limited competition.136 Second, the agency implemented a new policy to expedite the
review of generic drug applications in situations where competition is limited.137

FDA

Commissioner Scott Gottlieb stated, “[g]etting safe and effective generic products to market in an
efficient way, being risk-based in our own work and making sure our rules aren’t used to create
new obstacles to new competition can all help make sure that patients have access to more lowercost options.”138 In 2017 alone, over 1,000 generic drugs were approved and saved American
consumers and taxpayers approximately nine billion dollars.139
In May, Congress passed, nearly unanimously, both the Know the Lowest Price Act and
the Patient Right to Know Drug Prices Act.140 These laws ban the inclusion of pharmacy “gag
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clauses.”141 This federal action follows after twenty-nine states enacted laws to protect pharmacies
and pharmacists from penalties by a PBM for disclosing such information.142 The CBO estimates
the law will reduce the deficit by $40 million over the next decade.143
The Trump administration plans to further increase competition in 2019 by limiting
companies from using its 180-day exclusivity period to indefinitely delay real competition and
savings for consumers.144 The concern stems from first filers that receive tentative generic drug
approval, but then intentionally delay seeking final approval as a means to block competitions.145
Thus, first filers “park their exclusivity, and consumers are denied access to generic products and
must keep paying brand price.”146 In its 2019 budget proposal, HHS proposed legislation that
proposal “makes the tentative approval of a subsequent generic drug applicant that is blocked
solely by a first applicant’s 180-day exclusivity, where the first applicant has not yet received final
approval, a trigger of the first applicant’s 180-day exclusivity.”147 HHS believes that this proposal
will enhance competition and expedite timely access to generic drugs without compromising the
safety of the drug approval process. The proposal is estimated to create $1.8 billion in Medicare
savings over the next decade.148

The federal government is also implementing measures to improve negotiation, especially

141

S.2554, 115th Cong. § 2 (2018).
Richard Cauchi, States Regulating Pharmaceutical Benefit Managers, NATIONAL CONFERENCE OF STATE
LEGISLATURE (Oct. 11, 2018), http://www.ncsl.org/research/health/pbm-state-legislation.aspx.
143
CONGRESSIONAL BUDGET OFFICE, DIRECT SPENDING AND REVENUE EFFECTS FOR THE PATIENT RIGHT TO KNOW
DRUG PRICES ACT (2018).
144
THE UNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICES, AMERICAN PATIENTS FIRST: THE TRUMP
ADMINISTRATION BLUEPRINT TO LOWER DRUG PRICES AND REDUCE OUT-OF-POCKET COSTS 19 (2018).
145
UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICES, PUTTING AMERICA’S HEALTH FIRST: FY 2019
PRESIDENT’S BUDGET FOR HHS 15 (2018).
146
Id.
147
Id.
148
Id.
142

Nowak 23
in regard to Medicare. While the blueprint does not go so far as currently allowing Medicare to
directly negotiate prices with manufacturers, it does propose to alter regulations under Part C and
Part D of the Medicare Prescription Drug Program to allow for faster mid-year substitutes.149 Midyear substitutions permit Part D sponsors to immediately substitute generics for brand-name drugs
on the same or lower cost-sharing tier.150 Currently, Medicare participants face difficulties when
trying to substitute prescription drugs. Removing limitations on mid-year substitutes promotes the
use of generic drugs while decreasing the cost imposed on Medicare participants.
Outside of Medicare negotiations, the federal government plans to work alongside the
Department of Commerce, the U.S. Trade Representative, and the U.S. Intellectual Property
Enforcement Coordinator to address the disparity between drug prices in the U.S. compared to
other developed countries.151 However, no specific plans have been created or implemented.
The federal government also seeks to establish a maximum for out-of-pocket spending to
benefit those that spend the most on drugs.152 The plan suggests an “inflation penalty” in the form
of increased rebates from drug companies whose price increases are greater than the rate of
inflation.153 These changes would create strong incentives for manufacturers to negotiate lower
prices on over-priced drugs. The government also plans to combat the high list prices through
increased transparency; specifically, the FDA has sought to include list prices in direct-toconsumer (“DTC”) advertising.154 CMS has sought to hold manufacturers “accountable for high
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price increases, highlight drugs that have not taken price increases, and recognize when
competition is working with an updated drug pricing dashboard.”155 Critics contend that there is
no evidence that inclusion of list prices in DTC advertising will reduce pharmaceutical prices.
Instead, they argue that focus on price disclosure “is a distraction from additional action that would
benefit people—lowering prices.”156 Industry supporters believe that the measure will confuse,
mislead, and potentially harm patients. Jon Bigelo, an executive director of the Coalition for
Healthcare Communications wrote that it may, “discourag[e] them from initiating important
conversations with health providers and seeking medical care they need.”157
The federal government is also seeking to reduce out-of-pocket costs by implementing a
policy in which biosimilar drugs receive similar billing and payment codes under Medicare Part
B.158 Biosimilar drugs are FDA-approved, which are determined to have a biological or chemical
structure that is interchangeable with an FDA-approved biological product.159

The FDA

implemented the biosimilar process “as a way to provide more treatment options, increase access
to lifesaving medications, and potentially lower health care costs through competition.”160 It is
anticipated that this program will incentivize the development of additional lower-cost biosimilars
at a cheaper production cost while maintaining innovation among the pharmaceutical
manufacturers.161
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Lastly, the government has sought to reform the 340B Drug Discount Program. The 340B
program allows for qualified medical providers to purchase outpatient drugs at deep discounts.162
Because the program does not require these discounts to be passed onto patients or payers, the
program promotes financial stability by allowing participating providers to generate revenue from
the sale of these drugs.163 Effectively, the program allows these entities to “stretch scarce financial
resources as far as possible.”164 However, there are concerns that a lack of program oversight has
harmed the program.165 A 2016 review by the Office of Pharmacy Affairs in the Health Resources
and Services Administration (HRSA) found that HRSA audited less than two percent of all
participating providers.166 There are also concerns as to whether new participants are using the
340B benefits to improve healthcare access for low income patients or whether the 340B revenue
is used to increase revenue for hospital systems.167 Under the current statute, DSHs do not have
to demonstrate that the 340B revenues are utilized to enhance safety-net engagement.168 Rather,
they must only demonstrate that they provide a “sufficient amount” of inpatient services to
Medicaid and low-income Medicare beneficiaries.169 The Office of the Inspector General in 2014
found that most DSH hospitals did not offer discounted prices to uninsured patients.170
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As a result, the 340B PAUSE Act and the 340B HELP Act have been proposed. 171 The
two acts, taking slightly different approaches, propose a two year freeze on the approval of new
disproportionate share hospitals (DSHs), their clinics, and contract pharmacies.172 The two Acts
also propose increasing reporting requirements and enforcing eligibility criteria for DSHs and their
affiliates and imposing additional requirements for pharmacies.173

The enactment of this

legislation aims to increase accountability for those participating under the 340B program and
increase care for underprivileged patients by assuring that they receive the discounted prices as
provided under the current 340B program. Critics of the PAUSE Act and HELP Act contend that
there are issues regarding the scope and implementation. Critics also argue that freezing the
approval of additional DSHs would limit the accessibility for those that the 340B program seeks
to protect.
Since the Trump administration released its blueprint to reduce prescription drug prices
and out-of-pocket costs earlier this year, notable changes to the pharmaceutical sector have
occurred. Within the first 100 days, fifteen drug companies reduced their priced and either rolled
back planned price increases or committed to price freezes for the rest of 2018.174 During this
period, there was 60% fewer brand-drug price increases than during the same period in 2017.175
Price decreases occurred in 54% of generic and brand-name drugs than during the same period in
2017.176 Dan Best, Senior Advisor to the Secretary for Drug Pricing Reform, referred to the
rollbacks as “unprecedented recognition of fundamental changes going on in drug markets.”177
Additionally, the FDA in July of 2018 approved more generic drugs than in any other month in its
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history. These approvals included a generic version of the EpiPen and a biosimilar competitor for
a costly drug which fights infections in cancer patients.178
While these facts are an encouraging sign that the drug companies are reacting positively
to the increased scrutiny, many critics contest that the pharmaceutical industry improvements are
not correlated to the Trump administration’s blueprint. Health policy expert Rachel Sachs, an
associate professor of law at Washington University in St. Louis, opined that, “[t]he administration
seems to be feeling a need to deliver results quickly on the drug pricing front, and so they are
pointing to metrics like fewer price increases…rather than metrics that will be meaningful to
patients.”179 Additionally, HHS’s analysis was limited in its access to information and relied
instead upon a subscription database, AnalySource, which was unable to link directly to sales
volume.180 HHS acknowledged flaws in its analysis stating that its calculation was limited to
“simple counts and descriptives” of price increases.181

Because HHS lacked supporting

information and could not identify the magnitude of the price changes, HHS could not determine
the blueprint’s effectiveness on overall drug spending.182
Overall, the federal government has implemented a vast number of policies with the goal
of reducing the rising costs of pharmaceuticals. While some policies have seen immediate results,
others have not. Regardless of the determination of success, a reduction in pharmaceutical prices
is more likely to occur through increased federal legislation.
VII.

Proposed Strategies for Combatting the Increasing Costs

Various market, legislative, and societal approaches have been taken, with mixed results
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to impact the cost of pharmaceutical drugs. In evaluating the various approaches to combating the
rise in pharmaceutical prices, three measures provide the greatest upside: (1) allowing international
importation of approved drugs from Canada; (2) allowing direct negotiation for Medicare; and (3)
expediting approval of generic drugs.
A. Allowing importation of drugs from Canada
Allowing the importation of drugs from Canada will have the greatest impact on reducing
the cost of pharmaceuticals. Despite the apprehensions over the importation of pharmaceuticals
from Canada, importation legislation (1) does not pose any additional risk to the public’s health
and safety; and (2) would result in a significant reduction in the costs of covered products to the
American consumer.
Steep regulatory requirements embedded in the legislation would ensure that imported
drugs will not pose an additional risk to the public’s health and safety. Under the various
legislation, the importer must be licensed in accordance with Canada’s laws and state specific
pharmacy and wholesaler regulations.

Imported drugs must be approved by the Canadian

regulatory board, Health Canada; an agency that the FDA previously recognized and with whom
the parties agreed to cooperate on regulatory requirement and standards.183 Finally, the imported
drugs would only be distributed in-state, preventing interstate transportation and limiting possible
contamination.
Enacting this program will also result in a significant savings given the material difference
in drug prices between Canada and the U.S. According to Vermont Senator Bernie Sanders, drug

183

UNITED STATES-CANADA REGULATORY COOPERATION COUNCIL, JOINT FORWARD PLAN (2014) (The FDA has
also regulated standards of foreign drugs for distribution in the U.S., acknowledging that “[s]ome drugs approved in
the United States are ether fully manufactured overseas or made in the United States but contain some foreign
ingredients.” The FDA also acknowledged that it routinely inspects domestic and foreign drug manufacturing plants
to assure compliance with FDA standards. Press Release, Food and Drug Administration, FDA takes
unprecedented step toward more efficient global pharmaceutical manufacturing inspections (Oct. 31, 2017),
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm583057.htm).

Nowak 29
importation could save tax payers 6.8 billion dollars over ten years.184 While HHS disagrees with
Senator Sanders’ economic analysis, arguing that drug importation from Canada alone was
projected to produce only a negligible reduction in drug spending it is hard to argue that any
competition would not result in savings for American patients. 185 Furthermore, HHS continues to
rely on a 2004 Congressional Budget Office (“CBO”) study that would seemingly be outdated
given the significant developments in drug manufacturing, legislation and markets. As such, any
delay in implementing drug importation should be based on a new study to better understand the
economic benefits of such legislation.
B. Allowing Medicare to directly negotiate with pharmaceutical companies
Amending the Social Security Act, so that Medicare may negotiation with drug
manufacturers, pharmacies and PDP sponsors, and allow particular formulary or institute a price
structure for the reimbursement of covered Part D drugs would be a seismic step in combating
unbridled increases drug prices. The Center for Economic and Policy Research estimated federal
savings between $230 billion to $541 billion over ten years if Medicare negotiated the same prices
for drugs as countries where prices are set automatically.186 The analysis also estimated annual
savings of approximately fifteen billion dollars per years if Medicare paid the same prices as
Medicaid and the Veterans Association.187 Such an amendment has broad bipartisan support.
Furthermore, implementation would be widely supported by the American people. According to
the Henry J. Kaiser Family Foundation, among the public, Medicare negotiation is supported by
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96 percent of Democrats, 92 percent of Republicans and 92 percent of Independents.188
The impediment to such legislation appears to be the CBO 2004 study, and its analysis that
giving the HHS Secretary such authority would produce a “negligible effect on cost management
efforts.”189 Its conclusion relied on the expectation that the HHS Secretary would be limited in his
ability to negotiate substantial discounts. Instead, the Congressional Budget Office proposed that
savings could be achieved by authorizing the HHS Secretary to set drug prices administratively
rather than negotiating on prices.190 The Congressional Budget Office’s conclusion on savings
does not incorporate its propositions into its calculation.
Given the size and scope of the Medicaid budget and the minimal leverage that such a
consumer would have at any negotiating table, it is difficult to understand CBO’s conclusion that
HHS could not seek significant reductions in drug pricing. Even more compelling would be the
leverage that Medicare and the Veteran’s Association would add to any such negotiations.
Government, as a major purchaser of pharmaceuticals, should not be hampered in price
negotiations as any decreases, even negligible, in drug pricing would undoubtedly have significant
impacts on federal and state budgets.
C. Expediting approval of generic drugs
Expediting approval of generic drugs will aid in reducing pharmaceutical costs by
increasing competition in the open market. Manufacturers enjoy a lengthy period of noncompetition from with a patent, during which time they can charge a suitable, albeit not necessarily
reasonable, price to reward their innovation. But this monopoly period should not be enhanced by
a slow approval process for generic drugs.
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expiration, demonstrably shows significant price decreases.
Enacting HHS’s 180 day acceleration rule proposed in their 2019 budget, the first filers
would be encouraged to move their applications without delay; thereby getting generic drugs to
market faster. Furthermore, abbreviating the applications but not testing would further accelerate
the influx of generic drugs into the market. According to the FDA’s policy manual, applications
for generic products may receive expedited review if there are no blocking patents or exclusivities
and if the reference drug as less than three approved generics.191 Helping generic drugs into the
market quickly and safely will have the tremendous effect of decreasing drug prices.
VIII. Conclusion
Increased pharmaceutical costs have posed an ever-growing public health problem for the
nearly thirty years. These increases, well above the rate of inflation, have compromised some
individual’s health as they elect to forego treatment due to cost; causing long-term health
implications; and imposing costs upon the public health system. Understandably, pharmaceutical
companies need to be able to recoup investments in drug research and deliver returns for their
shareholders in order to continue to deliver innovative drugs.

However, without effective

mechanisms to limit increases in drug costs drug prices are causing a public health care crisis.
Drug prices are causing economic and physical harm to the Americans. As drug prices rise
without restraint, individuals, employers and federal and state governments must find ways to
cover these costs from strained resources. Moreover, studies show that patients skip taking some,
if not all, their prescribed medication because of drug prices, which in turn leads to additional
health problems, loss productivity and, in some cases, death. These cost add further burden on
society and can be measured in the billions.
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Federal and state governments have taken different approaches to limit drug increases and
their effect, from transparency regulations, use of generic drugs, payment restrictions and even
public humiliation. Some of these measures have worked, others moderately so, and still others
are obstructed by a lack of interest or belief that a particular legislation would be more than
negligibly helpful.
But given the change and, if fully embraced, by the purchasing factions, some measures
can significantly combat the rise in drug prices. Allowing greater competition by importing
medications from abroad, specifically Canada, would reduce drug prices. Further expediting the
approval and release of generic drugs into the market would force brand-name drugs to reduce
prices or risk significant loss in a drug’s market power. But the most significant change would be
to unleash the power of the federal government, not to impose regulations, but to use market power
to demand cost adjustments and limit price increases on drugs. Each of these measures on its own
would have significant, if not material, benefit to patients and providers. But taken together, these
three approaches would provide patients safe and affordable medications and the drug market to
operate in a more natural commercial market without the unnecessary restraints imposed on
providers and payers.

